세계 흡입 일산화질소 시장 규모는 2024년 10억 283만 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장이 17억 3,293만 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 5.64%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 북미가 시장을 독점하고 있으며, 2024년 시장 점유율은 77.7%를 초과했습니다. 흡입 일산화질소 시장 점유율은 신생아 중환자실(NICU)에서 흡입 일산화질소의 광범위한 사용을 지지하는 임상 가이드라인의 채택 증가와 함께 치료 방법을 개선하고 환자 예후를 개선할 수 있는 헬스케어 기술에 대한 투자 증가로 인해 성장하고 있습니다.
신생아 합병증 사례가 증가하면서 시장 성장에 박차를 가하고 있습니다. 병원과 의료진은 저산소성 호흡부전 신생아 및 급성 호흡곤란 증후군(ARDS)을 앓고 있는 환자를 위한 중요한 치료제로 흡입용 일산화질소를 사용하고 있습니다. 만성폐쇄성폐질환(COPD) 및 기타 폐질환의 발병률 증가는 흡입용 일산화질소에 대한 수요를 더욱 자극하고 있습니다. 이 외에도 약물전달 시스템의 발전으로 흡입 일산화질소 치료의 효율성과 접근성이 향상되고 있습니다. 또한, 헬스케어 인프라와 연구에 대한 투자 증가는 기술 혁신을 촉진하고 의료 용도를 확장하고 있습니다. 규제 당국의 승인과 유리한 의료 정책은 특히 선진국에서 폭넓은 채택을 뒷받침하고 있습니다.
미국은 여러 요인으로 인해 흡입 일산화질소 시장의 주요 지역이 되었습니다. 호흡기질환, 신생아 합병증, 폐 고혈압 등의 유병률 증가는 흡입 일산화질소 시장 전망을 밝게 하고 있습니다. 미국 정부 공식 웹사이트에 게시된 데이터에 따르면, 2025년 2월 현재 미국에서는 6.5%의 사람들이 호흡기세포융합바이러스(RSV)에 감염된 것으로 나타났습니다. 병원에서는 저산소성 호흡부전 신생아 및 ARDS 환자 치료에 흡입 일산화질소를 사용하고 있습니다. 첨단 의료 인프라와 의료 연구개발(R&D) 활동에 대한 강력한 투자로 혁신을 촉진하고, 약물전달 시스템을 개선하고, 치료 용도를 확장하고 있습니다. 또한, 대형 제약사의 존재가 제품 개발 및 공급을 가속화하고 있습니다. 노인 인구 증가와 호흡기 관리에 대한 대중의 인식이 높아짐에 따라 미국 내 흡입용 일산화질소에 대한 수요는 다양한 의료 현장에서 지속적으로 강화되고 있습니다.
신생아 호흡기질환의 유병률 증가
신생아의 호흡기질환 및 기타 후속 질환의 유병률 증가가 시장 성장을 견인하고 있습니다. 많은 미숙아들이 저산소성 호흡부전이나 지속성 폐고혈압을 앓고 있는데, 흡입 일산화질소는 산소 수준을 개선하고 체외막 산소화(ECMO)와 같은 침습적 치료의 필요성을 줄이는 데 도움이 됩니다. NIH에 따르면, 5세 미만 소아의 하기도 감염은 전 세계적으로 3,780만 건, 50만 1,910명의 사망, 4,480만 장애 조정 생존 연수를 차지합니다. 전 세계적으로 조산이 증가함에 따라 병원과 신생아실에서는 합병증을 줄이기 위해 이 치료법에 대한 의존도가 높아지고 있습니다. 규제 당국의 승인과 임상 가이드라인은 NICU에서 이 치료법의 보급을 더욱 촉진하고 있습니다. 또한, 현재 진행 중인 연구 개발 노력은 다른 신생아 질환의 치료에서 흡입 일산화질소의 새로운 용도를 모색하고 그 채택을 늘리는 데 도움을 주고 있습니다. 고액의 의료 투자와 신생아 관리 강화로 인해 흡입 일산화질소에 대한 수요가 증가하고 있으며, 신생아 호흡기질환의 중요한 치료법이 되고 있습니다.
노령인구 증가
노령인구 증가는 시장에 긍정적인 영향을 미치고 있습니다. 노인은 고혈압, 죽상동맥경화증, 말초동맥질환, 심부전, 혈전증에 걸리기 쉬우며, 이 모든 질환에 흡입 일산화질소에 의한 혈관 확장이 필요합니다. 2024년 MDPI의 보고에 따르면, 심부전 유병률은 연령에 따라 증가하여 55세 이하에서는 매년 약 1%, 70세 이상에서는 10%를 초과하는 것으로 나타났습니다. 또한, 노인은 COPD, 폐고혈압, ARDS 등의 질환에 걸리기 쉬워 효과적인 산소요법의 필요성이 대두되고 있습니다. 흡입 일산화질소는 산소의 흐름을 개선하고 폐압을 낮추는 작용을 하기 때문에 고령 환자에게 매우 중요한 치료법입니다. 평균 수명이 연장됨에 따라 의료 시스템은 고급 호흡기 치료에 중점을 두게 되었고, 병원과 요양 시설에서 흡입 일산화질소 채택률이 증가하고 있습니다. 호흡기 지원을 필요로 하는 노인이 증가함에 따라 흡입용 일산화질소에 대한 수요가 증가하고 있습니다.
첨단 헬스케어 인프라에 대한 투자 증가
첨단 의료 인프라에 대한 투자 증가는 흡입 일산화질소 시장의 성장을 가속하고 있습니다. 국제무역국(ITA)의 공식 웹사이트에 게재된 정보에 따르면, 2024년 인도 정부는 5개의 전인도 의학연구소(AIIMS) 센터를 새로 설립하고, 헬스케어 기술 발전을 촉진하기 위해 전국적으로 총 202개의 헬스케어 인프라 구상을 도입했습니다. 시설이 잘 갖추어진 병원, 신생아 전문 치료실, 현대식 중환자실에서는 저산소성 호흡부전, 폐고혈압, ARDS 등의 질병을 치료하기 위해 흡입 일산화질소가 널리 사용되고 있습니다. 첨단 의료기기가 사용 가능해짐에 따라 흡입 일산화질소 치료의 효율성이 향상되어 신생아부터 성인 호흡기질환까지 보다 효과적인 치료가 가능해졌습니다. 헬스케어 기술 및 R&D 활동에 대한 강력한 투자는 치료법을 더욱 향상시키고 환자의 예후를 개선하는 데 도움이 될 수 있습니다. 규제 당국도 기술 혁신을 지원하고 개선된 흡입 장치 및 약물전달 시스템 개발을 장려하고 있습니다.
The global inhaled nitric oxide market size was valued at USD 1,002.83 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,732.93 Million by 2033, exhibiting a CAGR of 5.64% from 2025-2033. North America currently dominates the market, holding a market share of over 77.7% in 2024. The inhaled nitric oxide market share is expanding, driven by the rising adoption of clinical guidelines that support the widespread utilization of inhaled nitric oxide in neonatal intensive care units (NICUs), along with increasing investments in healthcare technology to enhance treatment methods, leading to better patient outcomes.
The increasing cases of neonatal complications are fueling the market growth. Hospitals and healthcare providers use inhaled nitric oxide as a critical treatment for newborns with hypoxic respiratory failure and patients suffering from acute respiratory distress syndrome (ARDS). The rising incidence of chronic obstructive pulmonary disease (COPD) and other lung disorders is further catalyzing the demand for inhaled nitric oxide. Besides this, advancements in drug delivery systems improve the efficiency and accessibility of inhaled nitric oxide therapy. Moreover, the growing investments in healthcare infrastructure and research are encouraging innovations, expanding its medical applications. Regulatory approvals and favorable healthcare policies support wider adoption, especially in developed regions.
The United States has emerged as a major region in the inhaled nitric oxide market owing to many factors. The increasing prevalence of respiratory diseases, neonatal complications, and pulmonary hypertension is offering a favorable inhaled nitric oxide market outlook. According to the data published on the official website of the United States government, as of February 2025, 6.5% of people in the US were suffering from respiratory syncytial virus (RSV). Hospitals rely on inhaled nitric oxide to treat newborns with hypoxic respiratory failure and patients with ARDS. Advanced healthcare infrastructure and strong investments in medical research and development (R&D) activities promote innovations, improving drug delivery systems and expanding therapeutic applications. Additionally, the presence of major pharmaceutical companies accelerates product development and availability. With a growing elderly population and rising awareness among the masses about respiratory care, the demand for inhaled nitric oxide in the US continues to strengthen across various healthcare settings.
Growing prevalence of respiratory diseases in newborns
The increasing prevalence of respiratory and other subsequent diseases in newborns is propelling the market growth. Many premature babies suffer from hypoxic respiratory failure and persistent pulmonary hypertension, conditions where inhaled nitric oxide helps to improve oxygen levels and reduce the need for invasive procedures like extracorporeal membrane oxygenation (ECMO). According to the NIH, lower respiratory infections in children under five accounted for 37.8 Million cases, 501,910 deaths, and 44.8 Million disability-adjusted life years worldwide. As preterm births rise globally, hospitals and neonatal care units rely more on this therapy to reduce complications. Regulatory approvals and clinical guidelines further support its widespread use in NICUs. Additionally, ongoing R&D efforts are assisting in exploring new applications for inhaled nitric oxide in treating other neonatal conditions, increasing its adoption. With high healthcare investments and enhanced neonatal care, the demand for inhaled nitric oxide is rising, making it a crucial treatment for newborn respiratory disorders.
Rising geriatric population
The growing geriatric population is positively influencing the market. Older adults are more susceptible to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, all of which require inhaled nitric oxide for vasodilation. As per a 2024 MDPI report, heart failure prevalence rose with age, annually affecting about 1% of individuals under 55 and exceeding 10% in those over 70. The elderly population is also relatively more prone to conditions like COPD, pulmonary hypertension, and ARDS, creating the need for effective oxygen therapy. Inhaled nitric oxide helps to improve oxygen flow and reduce lung pressure, making it a crucial treatment for elderly patients. As life expectancy rises, healthcare systems focus on advanced respiratory treatments, leading to higher adoption of inhaled nitric oxide in hospitals and long-term care facilities. With the increasing number of elderly individuals requiring respiratory support, the demand for inhaled nitric oxide is rising.
Increasing investments in advanced healthcare infrastructure
The rising investments in advanced healthcare infrastructure are fueling the inhaled nitric oxide market growth. According to the information provided on the official website of the International Trade Administration (ITA), in 2024, the Indian Government launched five new All India Institute of Medical Sciences (AIIMS) centers and introduced a total of 202 healthcare infrastructure initiatives throughout the country to promote progress in healthcare technologies. Well-equipped hospitals, specialized neonatal care units, and modern intensive care facilities widely employ inhaled nitric oxide for treating conditions like hypoxic respiratory failure, pulmonary hypertension, and ARDS. The availability of advanced medical equipment improves the efficiency of inhaled nitric oxide therapy, making it more effective for both newborns and adults with respiratory disorders. Strong investments in healthcare technology and R&D activities further enhance treatment methods, leading to better patient outcomes. Regulatory bodies also support innovations, encouraging the development of improved inhalation devices and drug delivery systems.
Neonatal respiratory treatment held 86.1% of the market share in 2024. It is the primary therapy for newborns with hypoxic respiratory failure and persistent pulmonary hypertension. Inhaled nitric oxide helps to improve oxygen levels by relaxing blood vessels in the lungs, reducing the need for invasive procedures like ECMO. Hospitals widely adopt this treatment due to its effectiveness and safety in managing neonatal respiratory distress. The increasing number of preterm births and rising cases of neonatal lung disorders further drive the demand for inhaled nitric oxide. Regulatory approvals and clinical guidelines support the employment of inhaled nitric oxide in neonatal care, ensuring its availability in healthcare settings. Additionally, ongoing research focuses on expanding its applications in premature infants, increasing its market dominance. With advancements in neonatal care and better access to specialized treatments, the requirement for inhaled nitric oxide in neonatal respiratory therapy is growing, keeping it at the forefront of the market.
North America, accounting for 77.7%, enjoys the leading position in the market. The region is noted for its strong healthcare infrastructure, high prevalence of respiratory diseases, and increasing neonatal complications. The region has a well-developed hospital network that widely adopts inhaled nitric oxide therapy for conditions like hypoxic respiratory failure in newborns and ARDS in adults. The rising cases of COPD and pulmonary hypertension further drive the demand for inhaled nitric oxide. As per the information provided on the official website of the National Library of Medicine, as of April 2024, a sum of 29,445 male and 14,693 female cases of COPD were registered in workers in Canada. The ongoing R&D efforts by pharmaceutical companies contribute to continuous innovations in drug delivery systems and treatment protocols. Favorable regulatory policies and approvals from government agencies are supporting the market growth by ensuring safety. Additionally, high healthcare spending and reimbursement policies make inhaled nitric oxide treatments more available to patients.
United States Inhaled Nitric Oxide Market Analysis
The United States holds 93.20% of the market share in North America. The market in the United States is significantly driven by the increasing incidence of neonatal hypoxic respiratory failure, pulmonary hypertension (PAH), and ARDS. The Pulmonary Hypertension Association Registry anticipated that in 2022, the mortality rates for patients with PAH at 1, 2, and 3 years were 8%, 16%, and 21%, respectively, in the US. In 2011, the estimated prevalence of PAH was 109 per Million in commercially insured individuals and 451 per Million in Medicare patients, whereas in 2022, projections suggested approximately 40,000 adult PAH patients in the country. The high adoption of inhaled nitric oxide therapy in NICUs and post-cardiac surgery patients is driving the demand. The market is witnessing significant innovations, with companies developing advanced inhaled nitric oxide delivery systems that eliminate bulky gas cylinders, improving hospital efficiency and patient care. Regulatory approvals for portable and home-use inhaled nitric oxide devices are expanding accessibility beyond hospital settings. Increased competition is accelerating advancements in cost-effective and safer inhaled nitric oxide therapies. Moreover, the rising focus on digital health integration and precision dosing is supporting the market growth.
Europe Inhaled Nitric Oxide Market Analysis
The European market is expanding due to the strong healthcare infrastructure, rising cases of chronic lung diseases, and increasing preterm births requiring respiratory support. According to the European Environment Agency, in 2021, respiratory diseases were the third leading cause of death in its member countries, accounting for approximately 420,000 fatalities annually, with over 60% due to chronic respiratory diseases (CRDs). Environmental factors contributed to one-third of these deaths, nearly 80,000 preventable fatalities each year. Air pollution (14%), extreme temperatures (11%), occupational exposures (8%), and second-hand smoke (3%) were major risk causes. Regulatory frameworks, including CE Mark approvals, ensure high standards for inhaled nitric oxide therapy, promoting its use in hospitals and specialized clinics. Research into inhaled nitric oxide's role in treating PAH and post-operative care is driving the demand. Increased investments in precision medicine and artificial intelligence (AI)-based monitoring systems are improving therapy efficiency. Collaborations between healthcare institutions and pharmaceutical companies are leading to innovations.
Asia-Pacific Inhaled Nitric Oxide Market Analysis
The Asia-Pacific market is seeing a rapid rise attributed to increasing healthcare investments, rising neonatal respiratory disorders, and the growing awareness about advanced respiratory treatments. According to the India Brand Equity Foundation, India's healthcare sector was valued at USD 372 Billion in 2024, employing 7.5 Million people. Public healthcare spending reached 1.9% of GDP in FY24, while the hospital market, worth USD 98.98 Billion in 2023, is set to attain USD 193.59 Billion by 2032. China, Japan, and India are leading in inhaled nitric oxide adoption, driven by government initiatives to improve neonatal and pulmonary care. The expansion of tertiary hospitals and research centers is catalyzing the demand for advanced inhaled nitric oxide delivery systems. Industry leaders are investing in localized production and cost-effective solutions to refine market penetration.
Latin America Inhaled Nitric Oxide Market Analysis
In Latin America, the market is experiencing growth on account of the improved healthcare infrastructure, neonatal care awareness, and rising respiratory illness cases. An NIH review of 3,627 ARDS patients in 32 studies found 52% mortality rate in Latin America in 2023, varying by study type and region. Brazil and Mexico lead inhaled nitric oxide adoption through government pediatric and critical care initiatives. Investments in cost-effective respiratory therapies are enhancing local production and distribution. Portable inhaled nitric oxide delivery systems are expanding access in remote areas. Moreover, private-sector investments and worldwide collaborations are improving inhaled nitric oxide availability. Research into inhaled nitric oxide for respiratory infections and pulmonary conditions is further creating new market opportunities across Latin America.
Middle East and Africa Inhaled Nitric Oxide Market Analysis
The market in the Middle East and Africa is experiencing growth driven by rising investments in neonatal and critical care, particularly in GCC countries. Increasing respiratory diseases, premature births, and ARDS cases are driving hospital demand for inhaled nitric oxide therapy. During Q1 2024, the Dubai Health Authority (DHA) reported a 9% increase in healthcare settings and a 7% rise in professionals, licensing 12,319 specialists and 150 centers, totaling 5,020 facilities and 59,509 healthcare workers. Partnerships with international healthcare providers are promoting inhaled nitric oxide technology adoption.
Key players work on developing efficient solutions to meet the high inhaled nitric oxide market demand. They are investing in R&D activities to improve drug delivery systems and expand the medical applications of inhaled nitric oxide. They focus on creating modern inhalation devices that enhance treatment efficiency and patient outcomes. Strategic partnerships with healthcare providers and research institutions help to strengthen distribution networks and accelerate innovations. Regulatory approvals and compliance with safety standards ensure widespread adoption in hospitals and clinics. Key companies also wager on clinical trials to explore new therapeutic uses, increasing market potential. Marketing efforts and awareness campaigns educate healthcare professionals on the benefits of inhaled nitric oxide therapy, driving the demand. Additionally, broadening production capabilities and improving supply chain efficiency are making treatments more accessible. For instance, in February 2024, Third Pole Therapeutics reported the successful conclusion of a preliminary feasibility study for eNOfit, a portable delivery system for inhaled nitric oxide aimed at treating pulmonary hypertension linked to interstitial lung disease. The two-pound appliance enabled use at home and while on the go. This achievement promoted clinical trials and activated the final financing of Third Pole's USD 32 Million Series B funding round.